Anti-drug Abs

Antibody-drug conjugates (ADCs) are new-generation anti-cancer immunotherapeutic agents that accurately deliver cytotoxic agents to cancer cells to achieve caner elimination without damaging normal tissues. ADCs carry extremely high potent toxins and their pharmacokinetic properties and safety profile need to be extensively evaluated before deploying to human clinical trials. One crucial aspect in ADC pharmacokinetic (PK) property is the ratio of total and conjugated antibody after certain time period of deployment. This is usually assayed using immuno-colorimetric assay methods such as ELISA. To detect and quantify conjugated antibody, an agent that targets the drug portion of the ADC is desired.

Due to the high potency of ADC toxins, antibodies against these chemical compounds are difficult to develop. Only low dosages of a toxin can be applied for animal immunization and the corresponding immune response is low in small rodents. After devoting a tremendous amount of effort, Creative Biolabs has raised a series of antibodies, collectively anti-drug Abs, against ADC toxin antigens include MMAE, MMAF, DM1, DM4, Calicheamicin, Duocarmycin…. These anti-drug Abs will be valuable assets to facilitate the PK and safety evaluation of newly developed ADCs bearing these drugs.

List of the anti-drug Ab products